A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease (DUET ENCORE-CD)
27 août 2026 mis à jour par: Janssen Research & Development, LLC
A Phase 3, Randomized, Double-blind, and Active-controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn's disease (a long-term, progressive [worsens with time] and life-threatening disease of the intestine).
Aperçu de l'étude
Statut
Recrutement
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Estimé)
460
Phase
- Phase 3
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Study Contact
- Numéro de téléphone: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Lieux d'étude
-
-
-
Berlin, Allemagne, 14163
- Recrutement
- Krankenhaus Waldfriede Mitte
-
Dresden, Allemagne, 01307
- Recrutement
- Universitätsklinikum Carl Gustav Carus Dresden
-
Hanover, Allemagne, 30625
- Recrutement
- Medizinische Hochschule Hannover
-
Kiel, Allemagne, 24105
- Recrutement
- Universitatsklinikum Schleswig Holstein Kiel
-
Leipzig, Allemagne, 04103
- Recrutement
- EUGASTRO GmbH
-
Mannheim, Allemagne, 68167
- Recrutement
- Universitaetsklinikum Mannheim
-
Rostock, Allemagne, 18057
- Recrutement
- Universitaetsmedizin Rostock
-
-
-
-
-
AAI, Argentine, C1425BGC
- Recrutement
- GEDYT
-
La Plata, Argentine, 1896
- Recrutement
- Globalpsy
-
Mendoza, Argentine, M5500DPS
- Recrutement
- HIGEA
-
Quilmes, Argentine, B1878DVB
- Recrutement
- Cer Instituto Medico
-
-
-
-
-
Adelaide, Australie, 5000
- Recrutement
- Banksia Trials SA
-
Camperdown, Australie, 2050
- Recrutement
- Royal Prince Alfred Hospital
-
Clayton, Australie, 3168
- Recrutement
- Monash Medical Centre
-
East Melbourne, Australie, 3002
- Recrutement
- The Melbourne Gut Clinic Epworth Hospital
-
Kurralta Park, Australie, 5037
- Recrutement
- IBD SA
-
New Lambton Heights, Australie, 2305
- Recrutement
- John Hunter Hospital
-
South Brisbane, Australie, 4101
- Recrutement
- Mater Misericordiae Hospital
-
-
-
-
-
Edegem, Belgique, 2650
- Recrutement
- Universitair Ziekenhuis Antwerpen
-
Ghent, Belgique, 9000
- Recrutement
- Ghent University Hospital
-
Leuven, Belgique, 3000
- Recrutement
- Universitair Ziekenhuis Leuven
-
Roeselare, Belgique, 8800
- Recrutement
- Algemeen Ziekenhuis Delta
-
-
-
-
-
Curitiba, Brésil, 80430 180
- Recrutement
- CDC - Centro Digestivo de Curitiba
-
Macaé, Brésil, 27910-020
- Recrutement
- Cliged
-
Porto Alegre, Brésil, 90035 903
- Recrutement
- Hospital de Clinicas de Porto Alegre
-
Porto Alegre, Brésil, 90160 093
- Recrutement
- Hospital Ernesto Dornelles
-
Santo André, Brésil, 09080-110
- Recrutement
- Pesquisare Saúde
-
São Paulo, Brésil, 01236 030
- Recrutement
- BR Trials
-
São Paulo, Brésil, 04077-020
- Recrutement
- Rocco And Nazato Servicos Medicos Ltda
-
Votuporanga, Brésil, 15500-269
- Recrutement
- Integral Pesquisa e Ensino
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T5R 1W2
- Recrutement
- Gastroenterology and Internal Medicine Research Institute (GIRI)
-
Edmonton, Alberta, Canada, Code: T6K 4B2
- Recrutement
- South Edmonton Gastroenterology Research Clinic
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 2K5
- Recrutement
- GI Research Institute (G.I.R.I.)
-
-
Nova Scotia
-
Kentville, Nova Scotia, Canada, B4N 0A3
- Recrutement
- Viable Clinical Research
-
-
Ontario
-
London, Ontario, Canada, N6K 1M6
- Recrutement
- London Digestive Disease Institute
-
Mississauga, Ontario, Canada, L5M 2S4
- Recrutement
- West GTA Research Inc
-
Toronto, Ontario, Canada, M6A 3B4
- Recrutement
- Toronto Immune and Digestive Health Institute Inc
-
-
Quebec
-
Montreal, Quebec, Canada, H2X 0C1
- Recrutement
- CHUM - Centre hospitalier universitaire de Montreal
-
Montreal, Quebec, Canada, H3H1E3
- Recrutement
- Clinique IMD
-
-
-
-
-
Beijing, Chine, 100191
- Recrutement
- Peking University Third Hospital
-
Changzhou, Chine, 213004
- Recrutement
- Changzhou No 2 Peoples Hospital
-
Chongqing, Chine, 400014
- Recrutement
- Chongqing General Hospital
-
Guangzhou, Chine, 510655
- Recrutement
- Sun Yat-sen University - The Sixth Affiliated Hospital Guangdong Gastrointestinal Hospital
-
Hangzhou, Chine, 310000
- Recrutement
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine
-
Huai'an, Chine, 223300
- Recrutement
- Huai'an 1st Hospital
-
Ningbo, Chine, 315041
- Recrutement
- Ningbo Medical Center Lihuili Hospital
-
Zhuzhou, Chine, 412007
- Recrutement
- Zhuzhou Central Hospital
-
-
-
-
-
Busan, Corée du Sud, 48108
- Recrutement
- Inje University Haeundae Paik Hospital
-
Daejeon, Corée du Sud, 34943
- Recrutement
- The Catholic University of Korea Daejeon St Mary's Hospital
-
Gangnam Gu, Corée du Sud, 06351
- Recrutement
- Samsung Medical Center
-
Seoul, Corée du Sud, 05505
- Recrutement
- Asan Medical Center
-
-
-
-
-
Madrid, Espagne, 28031
- Recrutement
- Hosp. Univ. Infanta Leonor
-
Vigo, Espagne, 36312
- Recrutement
- Hosp. Alvaro Cunqueiro
-
-
-
-
-
Nantes, France, 44000
- Recrutement
- CHU de Nantes hotel Dieu
-
Reims, France, 51100
- Recrutement
- CHU de Reims
-
-
-
-
-
Hubballi, Inde, 580021
- Recrutement
- Sushruta Multispecialty Hospital and Research Centre
-
Hyderabad, Inde, 500032
- Recrutement
- Asian Institute of Gastroenterology
-
Jaipur, Inde, 302006
- Recrutement
- S. R. Kalla Memorial General Hospital
-
Kochi, Inde, 682018
- Recrutement
- Lisie Hospital
-
Secunderabad, Inde, 500003
- Recrutement
- Yashoda Super Speciality Hospitals
-
Surat, Inde, 395002
- Recrutement
- SIDS (Surat Institute of Digestive Sciences) Hospital and Research Centre
-
Surat, Inde, 395009
- Recrutement
- Gujarat Gastro and Vascular Hospital
-
-
-
-
-
Ashdod, Israël, 7747629
- Recrutement
- Assuta Medical Center
-
Haifa, Israël, 3109601
- Recrutement
- Rambam Medical Center
-
Haifa, Israël, 31048
- Recrutement
- Bnai Zion Medical Center
-
Holon, Israël, 5822012
- Recrutement
- Wolfson Medical Center
-
Jerusalem, Israël, 9103102
- Recrutement
- Shaare Zedek Medical Center
-
Kfar Saba, Israël, 44281
- Recrutement
- Meir Medical Center
-
Nahariya, Israël, 2210001
- Recrutement
- Galilee Medical Center
-
Petah Tikva, Israël, 4941492
- Recrutement
- Rabin Medical Center
-
Ramat Gan, Israël, 52621
- Recrutement
- Sheba medical center
-
Tel Aviv, Israël, 64239
- Recrutement
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Hamamatsu, Japon, 431-3192
- Recrutement
- Hamamatsu University Hospital
-
Hirosaki, Japon, 036-8545
- Recrutement
- National Hospital Organization Hirosaki National Hospital
-
Kagoshima, Japon, 892-0843
- Recrutement
- Kagoshima IBD Gastroenterology Clinic
-
Kashiwa, Japon, 277-0871
- Recrutement
- Tsujinaka Hospital Kashiwanoha
-
Kobe, Japon, 650 0017
- Recrutement
- Kobe University Hospital
-
Kumamoto, Japon, 860-8556
- Recrutement
- Kumamoto University Hospital
-
Kumamoto, Japon, 861-8520
- Recrutement
- Japanese Red Cross Kumamoto Hospital
-
Kumamoto, Japon, 862-0971
- Recrutement
- Takano Hospital
-
Minatoku, Japon, 108-8642
- Recrutement
- Kitasato University Kitasato Institute Hospital
-
Nagoya, Japon, 467-8602
- Recrutement
- Nagoya City University Hospital
-
Osaka, Japon, 540-0006
- Recrutement
- National Hospital Organization Osaka National Hospital
-
Osaka, Japon, 543-8555
- Recrutement
- Japanese Red Cross Osaka Hospital
-
Sapporo, Japon, 065-0033
- Recrutement
- Sapporo Higashi Tokushukai Hospital
-
Sapporo, Japon, 060-0033
- Recrutement
- Hokkaido P.W.F.A.C. Sapporo-Kosei General Hospital
-
Shimizu, Japon, 411-8611
- Recrutement
- National Hospital Organization Shizuoka Medical Center
-
Takamatsu, Japon, 760-0017
- Recrutement
- Takamatsu Red Cross Hospital
-
Yamanashi, Japon, 400-8506
- Recrutement
- Yamanashi Prefectural Central Hospital
-
-
-
-
-
Braga, Le Portugal, 4710 243
- Recrutement
- Uls Braga - Hosp. Braga
-
Viana do Castelo, Le Portugal, 4900-408
- Recrutement
- Ulsam - Hosp. Santa Luzia
-
-
-
-
-
Ampang, Malaisie, 68000
- Recrutement
- Hospital Ampang
-
Kajang, Malaisie, 43000
- Recrutement
- Sultan Idris Shah Hospital
-
Kota Kinabalu, Malaisie, 88586
- Recrutement
- Hospital Queen Elizabeth
-
Kuala, Malaisie, 20400
- Recrutement
- Hospital Sultanah Nur Zahirah
-
Petaling Jaya, Malaisie, 50603
- Recrutement
- University Malaya Medical Centre
-
-
-
-
-
Tromsø, Norvège, 9038
- Recrutement
- Universitetssykehuset Nord-Norge HF
-
Trondheim, Norvège, 7030
- Recrutement
- St. Olavs Hospital
-
Ålesund, Norvège, 6017
- Recrutement
- Alesund sjukehus
-
-
-
-
-
Nijmegen, Pays-Bas, 6525 GA
- Recrutement
- Radboud Umcn
-
-
-
-
-
Bydgoszcz, Pologne, 85 229
- Recrutement
- Centrum Medyczne Medis ManerMed Sp Z O O
-
Krakow, Pologne, 31-513
- Recrutement
- Centrum Medyczne PROMED
-
Lublin, Pologne, 20 582
- Recrutement
- Medrise Sp. z o.o.
-
Rzeszów, Pologne, 35-055
- Recrutement
- Centrum Medyczne 'Medyk' Sp. z o.o. K.
-
Szczecin, Pologne, 71-434
- Recrutement
- Twoja Przychodnia - Szczecinskie Centrum Medyczne
-
Zamość, Pologne, 22 400
- Recrutement
- ETG Zamość
-
-
-
-
-
Banská Bystrica, Slovaquie, 975 17
- Recrutement
- FNsP F. D. Roosevelta Banska Bystrica
-
Bratislava, Slovaquie, 811 09
- Recrutement
- Cliniq s.r.o.
-
Košice, Slovaquie, 040 13
- Recrutement
- ENDOMED s.r.o
-
Nitra, Slovaquie, 949 01
- Recrutement
- KM Management spol. s r.o.
-
Prešov, Slovaquie, 080 01
- Recrutement
- GASTRO I. s.r.o.
-
Prešov, Slovaquie, 080 01
- Recrutement
- Gastro LM s.r.o.
-
-
-
-
-
Taoyuan, Taïwan, 333
- Recrutement
- Linkou Chang Gung Memorial Hospital
-
-
-
-
-
Hradec Králové, Tchéquie, 500 12
- Recrutement
- Hepato-gastroenterologie HK, s.r.o.
-
Prague, Tchéquie, 190 00
- Recrutement
- ISCARE a.s.
-
Prague, Tchéquie, 14000
- Recrutement
- Fakultni Thomayerova nemocnice
-
-
-
-
-
Antalya, Turquie (Türkiye), 07100
- Recrutement
- Antalya Training and Research Hospital
-
Istanbul, Turquie (Türkiye), 34899
- Recrutement
- Marmara University Pendik Training Hospital
-
Istanbul, Turquie (Türkiye), 34093
- Recrutement
- Bezmialem University Medical Faculty
-
Izmir, Turquie (Türkiye), 35540
- Recrutement
- Izmir Şehir Hastanesi
-
Kocaeli, Turquie (Türkiye), 41001
- Recrutement
- Kocaeli University Medical Faculty
-
Mersin, Turquie (Türkiye), 33343
- Recrutement
- Mersin University Medical Faculty
-
-
-
-
California
-
Anaheim, California, États-Unis, 92805
- Recrutement
- Clinnova Research
-
Chula Vista, California, États-Unis, 91910
- Recrutement
- Gastro SB Clinic
-
Los Alamitos, California, États-Unis, 90720
- Recrutement
- United Medical Doctors
-
San Diego, California, États-Unis, 92123
- Recrutement
- Medical Associates Research Group, Inc.
-
-
Colorado
-
Colorado Springs, Colorado, États-Unis, 80907
- Recrutement
- Peak Gastroenterology Associates
-
-
Florida
-
Lakewood Rch, Florida, États-Unis, 34211
- Recrutement
- Florida Research Center Inc.
-
Miami, Florida, États-Unis, 33157-6575
- Recrutement
- Sanchez Clinical Research, Inc
-
Tampa, Florida, États-Unis, 33609
- Recrutement
- GCP Clinical Research
-
-
Georgia
-
Suwanee, Georgia, États-Unis, 30024
- Recrutement
- Atlanta Gastroenterology Specialists
-
-
Kentucky
-
Crestview Hills, Kentucky, États-Unis, 41017
- Recrutement
- Tri-State Gastroenterology Assoc
-
-
Louisiana
-
Lafayette, Louisiana, États-Unis, 70503
- Recrutement
- Gastroenterology Clinic of Acadiana
-
-
Michigan
-
Farmington Hills, Michigan, États-Unis, 48334
- Recrutement
- Michigan Center of Medical Research
-
-
New York
-
New York, New York, États-Unis, 10075
- Recrutement
- New York Gastroenterology Associates
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599
- Recrutement
- University of North Carolina Hospital
-
-
Ohio
-
Mentor, Ohio, États-Unis, 44060
- Recrutement
- Great Lakes Gastroenterology Research, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73114
- Recrutement
- Digestive Disease Specialists Inc
-
-
Oregon
-
Portland, Oregon, États-Unis, 97220
- Recrutement
- The Oregon Clinic
-
-
Tennessee
-
Cordova, Tennessee, États-Unis, 38018
- Recrutement
- Gastro One
-
-
Texas
-
Tyler, Texas, États-Unis, 75701
- Recrutement
- Tyler Research Institute, LLC
-
-
Washington
-
Tacoma, Washington, États-Unis, 98405
- Recrutement
- GI Alliance Tacoma
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion criteria:
- Have a diagnosis of Crohn's disease (CD) or fistulizing CD established greater than or equal to (>=) 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of CD
- Have moderately to severely active CD based on crohn's disease activity index (CDAI) criteria defined as a baseline CDAI score >= 220 but less than or equal to (<=) 450 and either: a. Mean daily stool frequency (SF) count >= 4.0, based on the unweighted CDAI component of the number of liquid or very soft stools or b. Mean daily AP score >= 2.0, based on the unweighted CDAI component of abdominal pain (AP)
- Have moderately to severely active ileal and/or colonic CD as assessed by central review of the screening video ileocolonoscopy based on simple endoscopic score for crohn's disease (SES-CD) criteria
- Have had an inadequate initial response, loss of response, or intolerance to previously approved systemic therapies
Exclusion criteria:
- Diagnosis of indeterminate colitis, microscopic colitis, ischemic colitis, ulcerative colitis (UC) or clinical findings highly suggestive of UC
- Complications of CD such as symptomatic bowel strictures or stenoses, or any other manifestation that may require intestinal surgery while enrolled in the study
- Presence of draining (that is, functioning) stoma or ostomy
- Has a history of short bowel syndrome, is missing greater than (>) 2 of the 5 ileocolonic segments, or has any other medical condition that could preclude or confound the ability to use efficacy assessment tools (such as CDAI) to assess response to study intervention
- Currently has or is suspected of having an abscess
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: JNJ-78934804
Participants will receive JNJ-78934804 induction dose, at Weeks 0, 4, and 8 followed by JNJ-78934804 maintenance dose, once every 4 weeks (q4w) starting at Week 12.
All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28.
Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the long-term extension (LTE) phase.
|
JNJ-78934804 will be administered subcutaneously.
Autres noms:
|
|
Comparateur actif: Guselkumab
Participants will receive guselkumab induction dose at Weeks 0, 4, and 8 followed by guselkumab maintenance dose q4w starting at Week 12.
All participants who meet the rescue criteria will receive JNJ-78934804 induction dose at Weeks 16, 20, and 24 followed by JNJ-78934804 maintenance dose q4w starting at Week 28.
Participants who complete double-blind treatment phase (Week 48) and who may benefit from continued study intervention in the opinion of the investigator will have the opportunity to enter the LTE phase.
|
Le guselkumab sera administré par voie sous-cutanée.
Autres noms:
JNJ-78934804 will be administered subcutaneously.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Co-Primary: Percentage of Participants with Clinical Remission at Week 48
Délai: At Week 48
|
Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score less than (<) 150.
CDAI scores range from 0 to approximately 600.
Higher score indicates higher disease activity.
|
At Week 48
|
|
Co-Primary: Percentage of Participants with Endoscopic Remission at Week 48
Délai: At Week 48
|
Endoscopic remission is defined as a Simple Endoscopic Score for Crohn's Disease (SES-CD) score of less than or equal to (<=) 4 with at least a 2-point reduction from baseline and no subscore greater than (>) 1 in any individual component.
The SES-CD is based on the evaluation of 4 endoscopic components (presence/size of ulcers, proportion of mucosal surface covered by ulcers, proportion of mucosal surface affected by any lesions, and presence/type of narrowing/strictures) across 5 ileocolonic segments.
SES-CD score can range from 0 to 56.
Higher scores indicating more severe disease.
|
At Week 48
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of Participants with Deep Remission at Week 48
Délai: At Week 48
|
Deep remission (composite endpoint) is defined as achieving both clinical remission and endoscopic remission at Week 48 at the participant level.
Clinical remission is defined as a CDAI score of <150 and Endoscopic remission is defined as a SES-CD score of <= 4 with at least a 2-point reduction from baseline and no subscore >1 in any individual component.
CDAI scores range from 0 to approximately 600.
Higher score indicates higher disease activity.
SES-CD score can range from 0 to 56.
Higher scores indicating more severe disease.
|
At Week 48
|
|
Percentage of Participants with Corticosteroid-Free (90-Day) Clinical Remission at Week 48
Délai: At Week 48
|
Corticosteroid-free (90-day) clinical remission at Week 48 is defined as clinical remission at Week 48 and not receiving corticosteroids for at least 90 days prior to Week 48.
Clinical remission is defined as a CDAI score of <150.
CDAI scores range from 0 to approximately 600.
Higher score indicates higher disease activity.
|
At Week 48
|
|
Percentage of Participants with Corticosteroid-Free (90-day) PRO-2 Remission at Week 48
Délai: At Week 48
|
Corticosteroid-free (90-day) patient-reported outcome(s) (PRO-2) remission at Week 48 is defined as an abdominal plan (AP) mean daily score less than or equal to (<=) 1 and stool frequency (SF) mean daily score <= 2.8, and no worsening of AP or SF from baseline, and not receiving corticosteroids for at least 90 days prior to Week 48.
|
At Week 48
|
|
Percentage of Participants with Sustained Clinical Remission
Délai: At Weeks 12 and 48
|
Sustained clinical remission is defined as clinical remission at Week 12 and Week 48.
Clinical remission is defined as CDAI score of <150.
CDAI scores range from 0 to approximately 600.
Higher score indicates higher disease activity.
|
At Weeks 12 and 48
|
|
Percentage of Participants with Histologic-Endoscopic Remission at Week 48
Délai: At Week 48
|
Histologic-endoscopic remission at week 48 is defined as achieving a combination of histologic remission and endoscopic remission at Week 48.
Histologic remission is defined as absence of neutrophils from the mucosa (both lamina propria and epithelium), no crypt destruction, and no erosions, or ulcerations or granulation tissue as assessed by the Robarts Histopathology Index.
Endoscopic remission is defined as a SES-CD score of <= 4 with at least a 2-point reduction from baseline and no subscore > 1 in any individual component.
|
At Week 48
|
|
Percentage of Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Response at Week 48
Délai: At Week 48
|
IBDQ response at Week 48 is defined as an improvement of at least 16 points in the IBDQ total score from baseline at Week 48.
IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate disease-specific health related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, AP), systemic function (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability).
Scores range from 32 to 224, with higher scores indicating better outcomes.
|
At Week 48
|
|
Percentage of Participants with Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29) Mental Component Summary Score (MCS) Response at Week 48
Délai: At Week 48
|
PROMIS-29 MCS response at Week 48 is defined as an improvement of at least 7 points in PROMIS-29 MCS score from baseline at Week 48.
The PROMIS-29 is a collection of short forms containing 4 items for each of 7 domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities).
PROMIS-29 also includes an overall average pain intensity 0-10 numeric rating scale.
The PROMIS-29 MCS will be assessed, which is primarily informed by domains of emotional distress (depression/anxiety) and fatigue as well as sleep disturbance where higher MCS scores reflect better mental health.
|
At Week 48
|
|
Percentage of Participants with Clinical Remission at Week 12
Délai: At Week 12
|
Clinical remission at Week 12 is defined as CDAI score <150 at Week 12. CDAI scores range from 0 to approximately 600.
Higher score indicates higher disease activity.
|
At Week 12
|
|
Percentage of Participants with Endoscopic Response at Week 12
Délai: At Week 12
|
Endoscopic response at Week 12 is defined as greater than (>) 50 percent (%) improvement from baseline in SES-CD score at Week 12 or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease.
SES-CD score can range from 0 to 56.
Higher scores indicating more severe disease.
|
At Week 12
|
|
Number of Participants with Adverse Events (AE) and Serious AEs (SAEs)
Délai: Up to approximately 3 years
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product.
An AE does not necessarily have a causal relationship with the intervention.
An SAE is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.
|
Up to approximately 3 years
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Directeur d'études: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
22 mai 2026
Achèvement primaire (Estimé)
12 juin 2028
Achèvement de l'étude (Estimé)
12 juillet 2030
Dates d'inscription aux études
Première soumission
5 mai 2026
Première soumission répondant aux critères de contrôle qualité
5 mai 2026
Première publication (Réel)
11 mai 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
28 août 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
27 août 2026
Dernière vérification
1 août 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 78934804CRD3001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
OUI
Description du régime IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Oui
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .